Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

被引：1
|
作者：
Li, Yijing [1 ]
Liu, Yang [1 ]
Che, Yuxuan [1 ]
McIntosh, Joseph [1 ]
Jordan, Alexa A. [1 ]
Leeming, Angela [1 ]
Andersen, Courtney L. [2 ]
Cidado, Justin [2 ]
Jin, Jingling [1 ]
Jiang, Vivian Changying [1 ]
Wang, Michael [1 ,3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[2] AstraZeneca, Oncol R&D, Waltham, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1867
引用
收藏
页码：1867 / +
页数：4
相关论文
共 36 条
  • [31] Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
    Wang, Michael
    Rossi, John M.
    Munoz, Javier
    Goy, Andre H.
    Locke, Frederick L.
    Reagan, Patrick M.
    Jacobson, Caron A.
    Hill, Brian T.
    Holmes, Houston
    Jaglowski, Samantha
    Peng, Weimin
    Zheng, Lianqing
    Fang, Xiang
    Xue, Allen
    Kloos, Ioana
    Bot, Adrian
    BLOOD, 2020, 136
  • [32] Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
    Tucci, Alessandra
    Re, Alessandro
    Pagani, Chiara
    Guidetti, Anna
    Dodero, Anna
    Marino, Fabrizio
    Casaroli, Ivana
    Soverini, Giulia
    Daffini, Rosa
    Balzarotti, Monica
    Campostrini, Giulia
    Lorenzi, Luisa
    Balzarini, Piera
    Facchetti, Fabio
    Carlo-Stella, Carmelo
    Corradini, Paolo
    Rossi, Giuseppe
    BLOOD, 2020, 136
  • [33] A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim M.
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Siddiqi, Rubina
    Reitan, John
    Castaigne, Gab
    Salles, Gilles
    BLOOD, 2022, 140 : 10296 - 10299
  • [34] Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small- cell Lung Cancer
    Pei, Junping
    Wang, Guan
    Wang, Aoxue
    Wu, Chengyong
    Pan, Xiaoli
    Shuai, Wen
    Bu, Faqian
    Zhu, Yumeng
    Wang, Yuxi
    Ouyang, Liang
    Li, Weimin
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (08) : 5719 - 5752
  • [35] Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma ( DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial
    Casulo, Carla
    Santoro, Armando
    Ando, Kiyoshi
    Le Gouill, Steven
    Ruan, Jia
    Radford, John
    Arcaini, Luca
    Pinto, Antonello
    Bouabdallah, Reda
    Izutsu, Koji
    Rule, Simon
    Munoz, Javier
    Casadebaig, Marie-Laure
    Fox, Brian
    Rettby, Nils
    Dell'Aringa, Justine
    Delarue, Richard
    Newhall, Kathryn
    Czuczman, Myron
    Cartron, Guillaume
    BLOOD, 2019, 134
  • [36] Golcadomide (GOLCA; CC-99282), a Potential First-in- Class Oral CELMoDT Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B- Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial
    Westin, Jason
    Hoffmann, Marc S.
    Vassilakopoulos, Theodoros
    Munoz, Javier L.
    Jurczak, Wojciech
    Yeh, Su-Peng
    Zimowska-Curylo, Dagmara
    Kwiatek, Michal
    Garcia-Sancho, Alejandro Martin
    Sudhindra, Akshay
    Gkasiamis, Argyrios
    Patel, Arpankumar
    Boucaud, Floriane
    Petel, Adrien
    Kaplan, Mark
    Basavanhally, Tara
    Li, Ju
    Nowakowski, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S482 - S482
1234